GeneBioTech Ltd Balance Sheet Health
Financial Health criteria checks 5/6
GeneBioTech has a total shareholder equity of ₩50.5B and total debt of ₩15.5B, which brings its debt-to-equity ratio to 30.7%. Its total assets and total liabilities are ₩71.7B and ₩21.2B respectively. GeneBioTech's EBIT is ₩3.3B making its interest coverage ratio -16.7. It has cash and short-term investments of ₩24.3B.
Key information
30.7%
Debt to equity ratio
₩15.51b
Debt
| Interest coverage ratio | -16.7x |
| Cash | ₩24.31b |
| Equity | ₩50.45b |
| Total liabilities | ₩21.20b |
| Total assets | ₩71.65b |
Recent financial health updates
Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden
Feb 17
Is Genebiotech (KOSDAQ:086060) A Risky Investment?
Nov 19Recent updates
GeneBioTech Ltd's (KOSDAQ:086060) Soft Earnings Are Actually Better Than They Appear
Nov 21
Market Cool On GeneBioTech Co. ,Ltd's (KOSDAQ:086060) Earnings
Aug 12We Like The Quality Of GeneBioTech Ltd's (KOSDAQ:086060) Earnings
Mar 22Read This Before Buying GeneBioTech Co. ,Ltd (KOSDAQ:086060) For Its Dividend
Apr 15Should GeneBioTech Ltd (KOSDAQ:086060) Be Disappointed With Their 90% Profit?
Mar 18Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden
Feb 17How Does Genebiotech Co., Ltd. (KOSDAQ:086060) Fare As A Dividend Stock?
Jan 10Is Genebiotech (KOSDAQ:086060) A Risky Investment?
Nov 19Financial Position Analysis
Short Term Liabilities: A086060's short term assets (₩55.6B) exceed its short term liabilities (₩18.8B).
Long Term Liabilities: A086060's short term assets (₩55.6B) exceed its long term liabilities (₩2.4B).
Debt to Equity History and Analysis
Debt Level: A086060 has more cash than its total debt.
Reducing Debt: A086060's debt to equity ratio has reduced from 44.7% to 30.7% over the past 5 years.
Debt Coverage: A086060's debt is not well covered by operating cash flow (13.9%).
Interest Coverage: A086060 earns more interest than it pays, so coverage of interest payments is not a concern.